How much revenue did Hansoh Pharmaceutical Group Company generate this year?
Hansoh Pharmaceutical Group Company has achieved a revenue of 12.14 B CNY this year.
Hansoh Pharmaceutical Group Company Revenue 2024
Hansoh Pharmaceutical Group Company Revenue
12.14 B CNY
Ticker
3692.HK
ISIN
KYG549581067
WKN
A2PLRC
In 2024, Hansoh Pharmaceutical Group Company's sales reached 12.14 B CNY, a 20.1% difference from the 10.1 B CNY sales recorded in the previous year.
The Hansoh Pharmaceutical Group Company Revenue history
| YEAR | REVENUE (undefined CNY) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 17.61 | 51,50 |
| 2028e | 16.25 | 55,82 |
| 2027e | 14.91 | 60,83 |
| 2026e | 14.05 | 64,55 |
| 2025e | 12.67 | 71,62 |
| 2024e | 12.14 | 74,75 |
| 2023 | 10.1 | 89,78 |
| 2022 | 9.38 | 90,73 |
| 2021 | 9.94 | 91,24 |
| 2020 | 8.69 | 90,76 |
| 2019 | 8.68 | 91,60 |
| 2018 | 7.72 | 92,19 |
| 2017 | 6.19 | 92,64 |
| 2016 | 5.43 | 92,69 |
Hansoh Pharmaceutical Group Company Revenue, EBIT, Net Income KYG549581067 · A2PLRC
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Hansoh Pharmaceutical Group Company, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hansoh Pharmaceutical Group Company from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hansoh Pharmaceutical Group Company’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Hansoh Pharmaceutical Group Company. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Hansoh Pharmaceutical Group Company’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Hansoh Pharmaceutical Group Company’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hansoh Pharmaceutical Group Company’s growth potential.
Hansoh Pharmaceutical Group Company Revenue, EBIT and net profit per share
| Date | Hansoh Pharmaceutical Group Company Revenue | Hansoh Pharmaceutical Group Company EBIT | Hansoh Pharmaceutical Group Company Net Income |
|---|---|---|---|
| 2029e | 17.61 B undefined | 0 undefined | 0 undefined |
| 2028e | 16.25 B undefined | 5.61 B undefined | 0 undefined |
| 2027e | 14.91 B undefined | 5.25 B undefined | 0 undefined |
| 2026e | 14.05 B undefined | 4.36 B undefined | 4.31 B undefined |
| 2025e | 12.67 B undefined | 3.85 B undefined | 3.79 B undefined |
| 2024e | 12.14 B undefined | 3.86 B undefined | 3.8 B undefined |
| 2023 | 10.1 B undefined | 2.65 B undefined | 3.28 B undefined |
| 2022 | 9.38 B undefined | 2.57 B undefined | 2.58 B undefined |
| 2021 | 9.94 B undefined | 2.96 B undefined | 2.71 B undefined |
| 2020 | 8.69 B undefined | 2.78 B undefined | 2.57 B undefined |
| 2019 | 8.68 B undefined | 2.8 B undefined | 2.56 B undefined |
| 2018 | 7.72 B undefined | 2.26 B undefined | 1.9 B undefined |
| 2017 | 6.19 B undefined | 1.91 B undefined | 1.6 B undefined |
| 2016 | 5.43 B undefined | 1.79 B undefined | 1.48 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2016 | 5.43 B CNY | 1.79 B CNY | 1.48 B CNY |
| 2017 | 6.19 B CNY | 1.91 B CNY | 1.6 B CNY |
| 2018 | 7.72 B CNY | 2.26 B CNY | 1.9 B CNY |
| 2019 | 8.68 B CNY | 2.8 B CNY | 2.56 B CNY |
| 2020 | 8.69 B CNY | 2.78 B CNY | 2.57 B CNY |
| 2021 | 9.94 B CNY | 2.96 B CNY | 2.71 B CNY |
| 2022 | 9.38 B CNY | 2.57 B CNY | 2.58 B CNY |
| 2023 | 10.1 B CNY | 2.65 B CNY | 3.28 B CNY |
| 2024e | 12.14 B CNY | 3.86 B CNY | 3.8 B CNY |
| 2025e | 12.67 B CNY | 3.85 B CNY | 3.79 B CNY |
| 2026e | 14.05 B CNY | 4.36 B CNY | 4.31 B CNY |
| 2027e | 14.91 B CNY | 5.25 B CNY | 0 CNY |
| 2028e | 16.25 B CNY | 5.61 B CNY | 0 CNY |
| 2029e | 17.61 B CNY | 0 CNY | 0 CNY |
Hansoh Pharmaceutical Group Company stock margins KYG549581067 · A2PLRC
The Hansoh Pharmaceutical Group Company margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hansoh Pharmaceutical Group Company. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hansoh Pharmaceutical Group Company.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Hansoh Pharmaceutical Group Company's sales revenue. A higher gross margin percentage indicates that the Hansoh Pharmaceutical Group Company retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Hansoh Pharmaceutical Group Company's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Hansoh Pharmaceutical Group Company's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hansoh Pharmaceutical Group Company's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hansoh Pharmaceutical Group Company. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hansoh Pharmaceutical Group Company's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Hansoh Pharmaceutical Group Company Margin History
| Hansoh Pharmaceutical Group Company Gross margin | Hansoh Pharmaceutical Group Company Profit margin | Hansoh Pharmaceutical Group Company EBIT margin | Hansoh Pharmaceutical Group Company Profit margin |
|---|---|---|---|
| 2029e | 89.78 % | 0 % | 0 % |
| 2028e | 89.78 % | 34.49 % | 0 % |
| 2027e | 89.78 % | 35.17 % | 0 % |
| 2026e | 89.78 % | 30.99 % | 30.64 % |
| 2025e | 89.78 % | 30.37 % | 29.93 % |
| 2024e | 89.78 % | 31.79 % | 31.34 % |
| 2023 | 89.78 % | 26.19 % | 32.44 % |
| 2022 | 90.73 % | 27.34 % | 27.54 % |
| 2021 | 91.24 % | 29.79 % | 27.31 % |
| 2020 | 90.76 % | 32.03 % | 29.56 % |
| 2019 | 91.6 % | 32.22 % | 29.45 % |
| 2018 | 92.19 % | 29.21 % | 24.64 % |
| 2017 | 92.64 % | 30.95 % | 25.79 % |
| 2016 | 92.69 % | 32.89 % | 27.17 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2016 | 92.69 % | 32.89 % | 27.17 % |
| 2017 | 92.64 % | 30.95 % | 25.79 % |
| 2018 | 92.19 % | 29.21 % | 24.64 % |
| 2019 | 91.6 % | 32.22 % | 29.45 % |
| 2020 | 90.76 % | 32.03 % | 29.56 % |
| 2021 | 91.24 % | 29.79 % | 27.31 % |
| 2022 | 90.73 % | 27.34 % | 27.54 % |
| 2023 | 89.78 % | 26.19 % | 32.44 % |
| 2024e | 89.78 % | 31.79 % | 31.34 % |
| 2025e | 89.78 % | 30.37 % | 29.93 % |
| 2026e | 89.78 % | 30.99 % | 30.64 % |
| 2027e | 89.78 % | 35.17 % | 0 % |
| 2028e | 89.78 % | 34.49 % | 0 % |
| 2029e | 89.78 % | 0 % | 0 % |
Hansoh Pharmaceutical Group Company Aktienanalyse
What does Hansoh Pharmaceutical Group Company do?
The Hansoh Pharmaceutical Group Co Ltd is a leading company in the pharmaceutical industry in China. It was founded in 1995 and has its headquarters in Lianyungang, with branches in Beijing and Shanghai. The company specializes in developing and producing innovative drugs for various diseases. It invests significant resources in research and development, collaborating with renowned research institutes and universities. Hansoh has a wide range of products in areas such as oncology, anesthesia, antibiotics, anti-infectives, and cardiovascular diseases. It has expanded its research and development activities in recent years and has partnerships with other pharmaceutical companies. The company mainly sells its products to hospitals and medical facilities in China. It is committed to strong corporate governance and sustainability, and it has been recognized for its environmental initiatives. Overall, Hansoh Pharmaceutical Group Co Ltd is a major player in the Chinese pharmaceutical industry. Hansoh Pharmaceutical Group Company ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Hansoh Pharmaceutical Group Company's Sales Figures
The sales figures of Hansoh Pharmaceutical Group Company originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Hansoh Pharmaceutical Group Company’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Hansoh Pharmaceutical Group Company's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Hansoh Pharmaceutical Group Company’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Hansoh Pharmaceutical Group Company stock
How much was the turnover of the company Hansoh Pharmaceutical Group Company compared to the previous year?
The revenue of Hansoh Pharmaceutical Group Company has increased by 20.1% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Hansoh Pharmaceutical Group Company?
The revenue of Hansoh Pharmaceutical Group Company is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Hansoh Pharmaceutical Group Company measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Hansoh Pharmaceutical Group Company so important for investors?
The revenue of Hansoh Pharmaceutical Group Company is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Hansoh Pharmaceutical Group Company pay?
Over the past 12 months, Hansoh Pharmaceutical Group Company paid a dividend of 0.19 CNY . This corresponds to a dividend yield of about 1.15 %. For the coming 12 months, Hansoh Pharmaceutical Group Company is expected to pay a dividend of 0.2 CNY.
What is the dividend yield of Hansoh Pharmaceutical Group Company?
The current dividend yield of Hansoh Pharmaceutical Group Company is 1.15 %.
When does Hansoh Pharmaceutical Group Company pay dividends?
Hansoh Pharmaceutical Group Company pays a quarterly dividend. This is distributed in the months of October, July, October, July.
How secure is the dividend of Hansoh Pharmaceutical Group Company?
Hansoh Pharmaceutical Group Company paid dividends every year for the past 0 years.
What is the dividend of Hansoh Pharmaceutical Group Company?
For the upcoming 12 months, dividends amounting to 0.2 CNY are expected. This corresponds to a dividend yield of 1.23 %.
In which sector is Hansoh Pharmaceutical Group Company located?
Hansoh Pharmaceutical Group Company is assigned to the 'Health' sector.
Wann musste ich die Aktien von Hansoh Pharmaceutical Group Company kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Hansoh Pharmaceutical Group Company from 7/17/2024 amounting to 0.142 CNY, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.
When did Hansoh Pharmaceutical Group Company pay the last dividend?
The last dividend was paid out on 7/17/2024.
What was the dividend of Hansoh Pharmaceutical Group Company in the year 2023?
In the year 2023, Hansoh Pharmaceutical Group Company distributed 0.23 CNY as dividends.
In which currency does Hansoh Pharmaceutical Group Company pay out the dividend?
The dividends of Hansoh Pharmaceutical Group Company are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Hansoh Pharmaceutical Group Company
Our stock analysis for Hansoh Pharmaceutical Group Company Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hansoh Pharmaceutical Group Company Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Hansoh Pharmaceutical Group Company Revenue
- Hansoh Pharmaceutical Group Company Net Income
- Hansoh Pharmaceutical Group Company P/E
- Hansoh Pharmaceutical Group Company P/S
- Hansoh Pharmaceutical Group Company EBIT
- Hansoh Pharmaceutical Group Company Dividend
- Hansoh Pharmaceutical Group Company Stocks
- Hansoh Pharmaceutical Group Company Market capitalization
- Hansoh Pharmaceutical Group Company Debt
- Hansoh Pharmaceutical Group Company Liabilities
- Hansoh Pharmaceutical Group Company Equity
- Hansoh Pharmaceutical Group Company AAQS
- Hansoh Pharmaceutical Group Company Employees
- Hansoh Pharmaceutical Group Company ROE
- Hansoh Pharmaceutical Group Company ROA
- Hansoh Pharmaceutical Group Company ROCE
